CD8A and neoplasm: In a recent study, a DNA vaccine encoding herpes simplex virus type 1 (HSV-1) glycoprotein D genetically fused to human HPV-16 oncoproteins E5, E6, and E7, induced antigen-specific CD8+ T-cell responses and conferred preventive resistance to transplantable murine TC-1 tumor cells [155].